Nanostim

For decades, pacemakers were a marvel of medical technology, but they had a persistent vulnerability: the leads. These wires, which connect the device to the heart, could fracture or cause complications. A company called Nanostim, led by CEO Drew Hoffman, envisioned a radical solution: a pacemaker so small it could be implanted directly into the heart, no leads required. This wasn't just an incremental improvement; it was a fundamental rethinking of the technology. The result was a device less than 10% the size of a conventional pacemaker, delivered via a minimally invasive catheter procedure. This eliminated the need for a surgical pocket in the chest and removed the risks associated with leads. In 2011, medical device giant St. Jude Medical recognized the game-changing potential, making an initial investment and securing an exclusive option to acquire the startup. By October 2013, Nanostim had achieved a critical milestone: CE mark approval in Europe. On the very same day, St. Jude Medical exercised its option, acquiring Nanostim in a significant deal. The acquisition cost $123.5 million upfront, with up to an additional $65 million based on future milestones. The move combined Nanostim’s pioneering technology with St. Jude's established commercialization power, aiming to revolutionize cardiac rhythm management for patients worldwide.